Neurimmune expands collaboration with AstraZeneca

Swiss immunotherapy firm Neurimmune announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with UK pharma major AstraZeneca’s (LSE: AZN) Alexion, AstraZeneca Rare Disease by entering into an exclusive global collaboration and license agreement to develop NI009, a pre-clinical human monoclonal antibody designed to target and deplete lambda light chain fibrils and deposits from affected tissues and organs in light chain (AL) amyloidosis.

Neurimmune is a clinical stage biopharmaceutical company building next generation therapeutics to address protein aggregation diseases with extensive experience in amyloid depletion.

The collaboration stands to leverage Alexion’s expertise in AL amyloidosis and strengths in late-stage rare disease drug development and expands upon the two companies’ existing Phase III development of cliramitug, an investigational human monoclonal antibody designed to deplete amyloid deposits in ATTR-CM.